Clinical Pharmacy

CP-003

CLINICAL PHARMACIST INTERVENTIONS ON PARENTERAL NUTRITION APPROPRIATENESS IN A TEACHING HOSPITAL

CP-002

PHARMACEUTICAL CARE SYSTEM FOR LIVER TRANSPLANT PATIENTS USING ELECTRONIC CONSULTATION

CP-001

IMPACT OF A PHARMACEUTICAL CARE PROGRAMME FOCUSED ON THE SOLID ORGAN TRANSPLANT PATIENT

CP-087

EVALUATION OF THE SAFETY AND EFFICACY OF MITOXANTRONE IN CYPRIOT PATIENTS WITH WORSENING FORMS OF MULTIPLE SCLEROSIS

CP-153

COMPARISON OF 5 HEALTH CARE PROFESSIONALS’RATINGS OF THE CLINICAL SIGNIFICANCE OF DRUG RELATED PROBLEMS

CP-045

ADEQUACY OF INTRAVENOUS IMMUNOGLOBULIN PRESCRIPTION AT A TEACHING HOSPITAL

CP-099

ECONOMIC IMPACT OF OPTIMISING BIOLOGIC THERAPIES FOR ARTHROPATHIES

CP-088

SURVIVAL TIME OF BIOLOGICAL TREATMENTS IN PSORIASIS

CP-095

IS THE EMERGENCY PHARMACIST ROLE ACCEPTED BY EMERGENCY DEPARTMENT STAFF?

CP-092

CLINICAL AUDIT OF PRESCRIPTIONS OF PROTHROMBIN COMPLEX CONCENTRATE IN A SMALL HOSPITAL

CP-066

INTERLEUKIN-28B POLYMOPHISM AS A PREDICTOR OF RESPONSE TO TELAPREVIR-BASED REGIMENS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION

CP-065

EFFECTIVENESS IN GENOTYPES 1B, 1A IN PATIENTS WITH HEPATITIS C VIRUS INFECTION TREATED WITH TELAPREVIR-BASED TREATMENT

CP-155

MISSED AND DELAYED DOSES OF PARKINSON’S MEDICINES AT NORTH BRISTOL NHS TRUST (NBT) (UK)

CP-150

IMPLEMENTATION OF AN INTEGRATED MULTIFACETED APPROACH TO IMPROVE CRUSHING PRACTICE ON HOSPITAL WARDS

CP-148

COMPARATIVE EFFICACY AND SAFETY OF TUMOUR NECROSIS FACTOR ALPHA BLOCKERS (ANTI-TNF) IN NON-FISTULIZING CROHN’S DISEASE

Pages